Document is current
Any future updates will be listed below
-
Authors
Roets, E.
Younger, E.
Jones, R. L.
Hollander, D.den
Desar, I. M. E.
Young, R. J.
Oosten, A. W.
de Haan, J. J.
Gelderblom, H.
Steeghs, N.
van der Graaf, W. T. A.
Husson, O.
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 6 February 2025
First Online: 27 February 2025
Declarations
:
: The authors confirm that all human research participants provided informed consent for both participation in the study and the publication of anonymized results, ensuring that no individual participant is identifiable.
: N. Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma, GlaxoSmithKline, Incyte, and Luszana. N Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Lixte, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, and Takeda. All outside the submitted work, all payments to the Netherlands Cancer Institute. W. van der Graaf: Advisory boards SpringworkTx, Agenus and PTC Therapeutics (all to the institute) and research grants from Eli Lilly (to the Institute). All remaining authors have declared no conflicts of interest.
